Trim MDT 30-35% to 65-70% of benchmark weight at ~$85.51; anchor core at $82.00 daily-close stop; defer fresh short to confirmed $89.45 retest
Underweight with 30-35% trim executed at market (~$85.51) to reduce MDT to 65-70% of benchmark weight, anchored by $82.00 daily-close stop on retained core; fresh short deferred to confirmed rejected retest of $89.45 50 SMA at 12.5% sizing with $90.50 stop; mechanical bull trigger at $88.01 reclaim with volume >20M, MACD stabilization, and RSI >48; Q2 FY27 print in mid-November as mandatory re-evaluation with downgrade to Sell on confirmed close below $82 on volume >12M or earnings miss.
| Position | Action |
|---|---|
| Current MDT position exceeds benchmark weight | Trim 30-35% of MDT exposure at market (~$85.51) to reduce to 65-70% of benchmark weight |
| MDT rallies to $89.45 (50 SMA) on clearly rejected retest with declining volume | Initiate fresh short at 12.5% of healthcare allocation with $90.50 stop (above recent high, proper ATR room) |
| Confirmed close >$88.01 (10 EMA reclaim) on volume >20M with MACD histogram stabilizing AND RSI >48 | Add 1-1.5% of portfolio on mechanical bull trigger |
| Q2 FY27 bull scenario: Revenue >+8% organic ex-M&A AND op margin >19.5% AND close >$89.50 | Add 15-20% of position, retest to Hold |
| Q2 FY27 bear scenario: Revenue <+5% OR margin <18% OR confirmed close <$82 on volume >12M | Exit remaining position, downgrade to Sell |
| Rejection of trader's fresh short at $87.84 with $90 stop | Decline entry—10 EMA is overhead resistance not trigger, and stop-to-ATR ratio ($2.16/$2.09) structurally weak |
MDT is a contrarian buy at $87 on the 200 SMA: Q1 FY27 delivered +13.7% revenue growth and +40.7% EPS growth while trading at 13.3x forward P/E with 3.31% yield, and the earnings inflection combined with surgical robotics and diabetes pipeline catalysts creates asymmetric risk/reward with 8% upside to $94.
| Indicator | Value | Signal |
|---|---|---|
| Close (2026-10-06) | $87.09 | neutral |
| 10 EMA | 87.84 | bearish |
| 50 SMA | 89.45 | bearish |
| 200 SMA | 87.07 | neutral |
| RSI | 42.48 | bearish |
| MACD | -0.83 | bearish |
| MACD Signal | -0.40 | bearish |
| MACD Histogram | -0.43 | bearish |
| Bollinger Mid (20 SMA) | 89.52 | bearish |
| Bollinger Upper | 94.00 | bearish |
| Bollinger Lower |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Current position overweighted; 200 SMA broken on heaviest volume of year; sequential revenue stalling at $9.756B with $264M inventory build; 5%+ 10Y making yield uncompetitive
Then: Execute 30-35% trim at market (~$85.51)
↩ rebuts: “Bear's technical breakdown case”
EV: +8.0% · concedes: USD strength is a translation headwind affecting revenue growth; Technical setup looks ugly on the surface; MACD expanding negative; Bear's 200 SMA breakdown call could prove correct
MDT at $87 is a broken technical setup where the 200 SMA support failed within 24 hours on heavy volume distribution, forward earnings skepticism is warranted given sequential revenue decline and inventory build, and the 3.31% dividend yield is uncompetitive versus the 5%+ risk-free rate, creating a high-probability short setup into resistance.
EV: $80 (3-month target) · concedes: MDT is a high-quality business relative to peers; MiniMed 780G is a credible diabetes product; Hugo has been gaining regulatory approvals; Q1 FY27 EPS +40.7% YoY is impressive on the surface
→ vs conservative: The 3.31% dividend yield is no longer competitive with 10-year Treasuries at 170 basis points higher; dividend aristocrat brand appeal is being repriced by the rate environment and should not be used as a shield to ignore the risk-reward deterioration
→ vs conservative: The 13.3x forward P/E is not a cushion but a warning sign — it reflects earnings normalization assumptions that could fail if Q2 FY27 does not produce a clean beat with raised guidance
→ vs conservative: Currency exposure with approximately 50% non-U.S. revenue is an unpriced headwind as dollar strengthens on rate differential; conservative guidance on FX could collapse the forward P/E multiple cushion overnight
→ vs neutral: The October 6th and 7th volume signatures (52.1M and 55.9M shares respectively on down days) are textbook distribution patterns, not a balanced tape; the marginal seller is exhausting the marginal buyer
→ vs neutral: The 200-day moving average at $87.07, lower Bollinger band at $85.03, and May swing lows at $76.50 define a clear technical path of least resistance — down, not sideways
→ vs neutral: When 10 EMA, 200 SMA, and VWMA all align as resistance overhead, 'neutral' is not a defensible stance but a costly one that ignores price running ahead of every weighted reference point
| 85.03 |
| bearish |
| ATR (14) | 2.09 | neutral |
| VWMA | 87.94 | bearish |
Support: 87.07 · 85.03 · 76.5 | Resistance: 87.84 · 89.45 · 89.52 · 93.4 · 94
MDT is in a bearish intermediate-term trend that has accelerated over the past three weeks. Price has broken below the 50 SMA, MACD is negative and expanding, RSI is in bearish territory at 42.48, and volume has surged to record levels during the decline — a classic sign of distribution rather than capitulation lows. Price is currently sitting directly on the 200 SMA at $87.07 (within $0.02 of the $87.09 close), making this a critical structural pivot. A decisive close below the 200 SMA would be a major technical breakdown signal and could trigger stop-loss cascades, while RSI at 42.48 leaves room for further downside before reaching oversold territory.
Market Cap
$109.38 B
P/E (TTM)
21.0x
Forward P/E
13.3x
P/B
2.18x
PEG Ratio
1.56
Dividend Yield
3.31%
Beta
0.567
Gross Margin
65.3%
Operating Margin
19.3%
Profit Margin
13.9%
ROE
10.6%
ROA
5.1%
EBITDA (TTM)
$10.41 B
Revenue (TTM)
$37.542B
Net Income (TTM)
$5.23B
EPS (TTM)
$4.07
Forward EPS
$6.41
Current Ratio
2.07
Cash + ST Investments
$8.819B
Working Capital
$12.59B
Goodwill
$43.187B
Total Debt
$28.153B
Net Debt
$26.410B
Debt/Equity
0.56
Net Debt/EBITDA
~2.5x
Operating CF (TTM)
~$7.97B
Free Cash Flow (TTM)
$5.41B
CapEx (Quarterly)
~$480M
52-Week High
$106.33
52-Week Low
$73.31
50-Day MA
$90.07
200-Day MA
$88.54
Shares Outstanding
1.285 B
Strengths
Concerns
HOLD with positive lean — Medtronic is a defensive Dividend Aristocrat with reaccelerating revenue growth (+13.7% YoY in Q1 FY27) and an earnings inflection (EPS +40.7% YoY), trading at an attractive forward P/E of 13.3x versus 21.0x TTM. The stock offers a compelling risk-reward given its 3.31% yield, robust $5.4B TTM free cash flow, and healthy 2.5x leverage profile, but the rating remains HOLD pending technical confirmation as MDT trades below both its 50-day ($90.07) and 200-day ($88.54) moving averages with negative momentum. Near-term fair value range of $90-$98 is suggested based on 16-17x forward EPS of $6.41.
Macro: Hawkish rate regime: 10-year Treasury at highest since 2002 (biggest monthly gain since 2022), Fed officials signaling 'more work to do' on inflation, Goldman Sachs and Moody's Zandi warning on rising rate damage to economy. Iran war cited as inflation driver not just via oil but broader goods/services channels. September jobs report missed but Fed quickly reframed as 'no green light to cut.' Equity indices (S&P 500, Nasdaq) at record highs led by Nvidia/AMD with narrow, AI-driven leadership. Bitcoin below $83,000 and gold falling on stronger dollar. Prediction markets: 96% no Fed cuts in 2026, US recession 6%, UK recession 7%, Japan recession 4%.